| Literature DB >> 34104096 |
Mon-Chien Lee1, Yi-Ju Hsu1, Chin-Shan Ho1, Chun-Hao Chang1, Ching-Wen Liu2, Chi-Chang Huang1, Wen-Dee Chiang2.
Abstract
Excessive exercise load can cause muscle soreness and fatigue, as well as inflammation and oxidative stress. Lemon verbena (Aloysia triphylla; Lippia citriodora) is often used as a spice in tea or beverages. Its leaves are rich in polyphenols, which have antioxidant and anti-inflammatory bioactivities. In the present study, we investigated whether supplementation with Planox® lemon verbena extract (LVE) could improve muscle damage and biochemical indicators after exhaustive exercise challenge. All subjects (30 males and 30 females) underwent a double-blind trial and were randomly divided into a placebo group (0 mg/human/day) and an LVE supplement group (400 mg/human/day), with gender-equal distribution. All subjects started supplementation 10 days before exhaustive exercise and continued it until all tests were completed. Before the intervention, after the exhaustive exercise, and on the following 3 days, the participants underwent 12-minute Cooper running/walking; blood collection; assessments of pain, muscle stiffness, maximum jump heights, and isometric maximum muscle strength. The results showed that supplementation with LVE effectively increased GPx and reduced CK, IL-6, 8-OHdG and muscle pain after the exhaustive exercise, but it had significant effect on strength recovery. In summary, LVE is a safe and edible natural plant extract that can reduce muscle damage and soreness after exercise. This trial was registered at clinicaltrials.gov as NCT04742244. © The author(s).Entities:
Keywords: Lemon verbena; inflammation.; muscle injury; oxidative stress
Mesh:
Substances:
Year: 2021 PMID: 34104096 PMCID: PMC8176190 DOI: 10.7150/ijms.60726
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Basic information data of the subjects.
| Characteristics | Placebo | LVE |
|---|---|---|
| 21.0 ± 0.4 | 21.3 ± 0.4 | |
| 167.5 ± 1.1 | 167.8 ± 1.7 | |
| 62.7 ± 1.3 | 62.7 ± 1.9 | |
| 22.3 ± 0.4 | 22.1 ± 0.4 | |
| 27.9 ± 1.0 | 28.0 ± 1.2 | |
| 20.6 ± 1.3 | 20.6 ± 1.4 | |
| 87.0 ± 1.0 | 87.0 ± 1.0 | |
| 175.0 ± 4.0 | 175.0 ± 4.0 | |
| 67.0 ± 3.0 | 67.0 ± 2.0 | |
| 66.1 ± 1.4 | 66.2 ± 1.4 | |
| 86.5 ± 2.5 | 86.6 ± 3.4 |
Data are expressed as mean ± SEM. There were no significant group differences in the basic information data. BMI, body mass index; LBM, lean body mass; FBM, fat body mass; TC, total cholesterol; TG, triglyceride; HDL, high-density lipid; LDL, low-density lipid.
The LVE supplementation on the assessment of muscle soreness by Myoton.
| Characteristics | Frequency [Hz] | Stiffness [N/m] | Decrement | |||
|---|---|---|---|---|---|---|
| Placebo | LVE | Placebo | LVE | Placebo | LVE | |
| 13.5 ± 0.2 | 13.5 ±0.2 | 204 ± 5 | 204 ± 6 | 1.10 ± 0.0 | 1.10 ± 0.0 | |
| 13.4 ± 0.1 | 13.2 ± 0.2 | 201 ± 5b | 193 ± 6a | 1.12 ± 0.0 | 1.10 ± 0.0 | |
| 13.7 ± 0.1 | 13.2 ± 0.2 | 211 ± 5 | 196 ± 6 | 1.11 ± 0.0 | 1.05 ± 0.0 | |
| 13.5 ± 0.2b | 13.3 ± 0.2a | 186 ± 6* | 175 ± 5* | 1.08 ± 0.0 | 1.04 ± 0.0 | |
| 15.8 ± 0.2 | 15.7 ± 0.4 | 280 ± 6 | 280 ± 9 | 1.37 ± 0.0 | 1.36 ± 0.1 | |
| 16.4 ± 0.3* | 16.0 ± 0.3 | 291 ± 7b | 274 ± 5a | 1.51 ± 0.0 | 1.37 ± 0.0 | |
| 17.7 ± 0.4* | 16.7 ± 0.3 | 303 ± 9* | 306 ± 8 | 1.45 ± 0.1 | 1.39 ± 0.0 | |
| 17.9 ± 0.4b,* | 16.5 ± 0.2a | 303 ± 8* | 285 ± 7 | 1.40 ± 0.0 | 1.31 ± 0.0 | |
Data are presented as mean ± SEM. Different superscript letters (a, b) indicate significant difference between groups at p < 0.05, and baseline is compared with post-3h, 24h, 48h, respectively. Administration effects were statistically analyzed with a paired Student's t-test, compared with baseline, * p < 0.05.
The VAS score to assess muscle pain.
| Characteristics | Medial quadriceps | Lateral quadriceps | ||
|---|---|---|---|---|
| Placebo | LVE | Placebo | LVE | |
| 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | |
| 2.3 ± 0.4* | 1.9 ± 0.4* | 2.3 ± 0.4* | 1.9 ± 0.4* | |
| 4.0 ± 0.4* | 3.3 ± 0.4* | 4.1 ± 0.4b,* | 2.7 ± 0.4a,* | |
| 4.4 ± 0.4b,* | 2.5 ± 0.4a,* | 4.0 ± 0.4b,* | 2.0 ± 0.3a,* | |
| 3.0 ± 0.4* | 1.5 ± 0.3* | 2.8 ± 0.4b,* | 1.3 ± 0.3a,* | |
Data are presented as mean ± SEM. Different superscript letters (a, b) indicate significant difference between groups at p < 0.05, and baseline is compared with post-3h, 24h, 48h, and 72h, respectively. Administration effects were statistically analyzed with a paired Student's t-test, compared with baseline, * p < 0.05.
LVE supplementation effects on muscle strength and jumping force.
| Characteristics | Baseline | 24h | 48h | |||
|---|---|---|---|---|---|---|
| Placebo | LVE | Placebo | LVE | Placebo | LVE | |
| 11.08 ± 0.50 | 11.17 ± 0.58 | 9.14 ± 0.53a,* | 10.69 ± 0.56b | 10.39 ± 0.66 | 10.91 ± 0.71 | |
| 3.67 ± 0.31 | 3.68 ± 0.29 | 3.20 ± 0.25* | 3.21 ± 0.21 | 3.32 ± 0.29* | 3.46 ± 0.25 | |
| 0.52 ± 0.04 | 0.52 ± 0.04 | 0.63 ± 0.03* | 0.60 ± 0.03* | 0.58 ± 0.03 | 0.60 ± 0.03* | |
| 833 ± 38 | 838 ± 45 | 745 ± 29* | 792 ± 42* | 756 ± 28* | 796 ± 43* | |
| 9.55 ± 0.23 | 9.52 ± 0.26 | 10.32 ± 0.21* | 10.14 ± 0.22* | 10.02 ± 0.20* | 9.88 ± 0.23 | |
| 0.52 ± 0.01 | 0.53 ± 0.02 | 0.53 ± 0.01 | 0.53 ± 0.02 | 0.53 ± 0.01 | 0.52 ± 0.01 | |
| 508 ± 23 | 507 ± 24 | 504 ± 19 | 512 ± 23 | 501 ± 19 | 509 ± 22 | |
Data are presented as mean ± SEM. Different superscript letters (a, b) indicate significant difference between groups at p < 0.05, and baseline is compared with post-, 24h, and 48h, respectively. Administration effects were statistically analyzed with a paired Student's t-test, compared with baseline, * p < 0.05. RFD, rate of force development.
LVE supplementation effect on isometric maximum muscle strength.
| Characteristics | Baseline | 24h | 48h | |||
|---|---|---|---|---|---|---|
| Placebo | LVE | Placebo | LVE | Placebo | LVE | |
| 1190 ± 78 | 1198 ± 84 | 1024 ± 62* | 1135 ± 73 | 1059 ± 58* | 1172 ± 76 | |
| 17.98 ± 1.12 | 18.12 ± 1.11 | 14.80 ± 0.87* | 15.54 ± 0.82* | 16.49 ± 0.99* | 17.80 ± 0.99 | |
| 7145 ± 794 | 7127 ± 590 | 6486 ± 595 | 6737 ± 504 | 6999 ± 530 | 7677 ± 682 | |
| 2.48 ± 0.14 | 2.50 ± 0.16 | 3.24 ± 0.18* | 2.71 ± 0.19 | 2.98 ± 0.23 | 2.46 ± 0.14 | |
| 0.17 ± 0.01 | 0.17 ± 0.01 | 0.2 ± 0.05 | 0.19 ± 0.03 | 0.20 ± 0.03 | 0.17 ± 0.01 | |
Data are presented as mean ± SEM. Different superscript letters (a, b) indicate significant difference between groups at p < 0.05, and baseline is compared with post-, 24h, and 48h, respectively. Administration effects were statistically analyzed with a paired Student's t-test, compared with baseline, * p < 0.05. RFD, rate of force development.
LVE supplementation effect on the blood biochemical.
| Characteristics | Baseline | 3h | 24h | 48h | ||||
|---|---|---|---|---|---|---|---|---|
| Placebo | LVE | Placebo | LVE | Placebo | LVE | Placebo | LVE | |
| 87 ± 1 | 87 ± 1 | 95 ± 1 | 95 ± 2 | 101 ± 1 | 101 ± 1 | 99 ± 1 | 98 ± 1 | |
| 27 ± 1 | 27 ± 1 | 27 ± 1 | 27 ± 2 | 26 ± 1 | 27 ± 2 | 28 ± 1 | 28 ± 2 | |
| 21 ± 1 | 22 ± 2 | 21 ± 1 | 20 ± 1 | 19 ± 1 | 17 ± 1 | 17 ± 1 | 20 ± 2 | |
| 460 ± 8 | 442 ± 11 | 445 ± 6 | 441 ± 9 | 437 ± 6 | 420 ± 9 | 438 ± 7 | 428 ± 12 | |
Data are presented as mean ± SEM. AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase.